Plus Therapeutics announced it has been selected for funding by the Department of Defense office of the Congressionally Directed Medical Research Programs. The award is expected to commence in Q3 2024 and will support the planned expansion of the Company’s clinical trial for pediatric brain cancer. “This recent award further extends our current cash runway in the second half of 2025, while supporting the 2024 expansion of our clinical development activities,” said Marc H. Hedrick, M.D., President & CEO of Plus Therapeutics. “In 2023, the Company applied for approximately $7 million in grant funding, and we plan to file for more than $10 million in funding in 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Is PSTV a Buy, Before Earnings?
- Plus Therapeutics appoints Andrew Brenner, Barbara Blouw to management team
- Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team
- Plus Therapeutics announces validation, implementation of CSF-01 diagnostic
- Plus Therapeutics CEO’s Insightful Presentation Now Available
